Scorpius BioManufacturing

Scorpius BioManufacturing Contract Manufacturing & Development (CDMO) Profile

Scorpius BioManufacturing is an integrated CDMO focused on rapidly advancing your mammalian and microbial biologic programs to the clinic and beyond. With end-to-end capabilities from discovery to limited-scale commercial production, we provide a broad array of R&D, analytical testing, and manufacturing services to pharmaceutical and biotech companies. With an experienced team and new, purpose-built, U.S. facilities, Scorpius is dedicated to easily accessible, transparent collaboration and flexible biologics biomanufacturing.

CDMO Services:
Biologics; Cell & Gene Therapy Analytical Development; Formulation Development; ICH Stability Testing; Process Development Antibodies; Fusion Proteins; Recombinants + other Proteins; Protein Vaccines; Plasmid DNA; Live Biotherapeutic Products

Year Founded: 2021

Head Office: San Antonio, United States

Number of Facilities: 1-2

Facility locations: North America

Website: Visit the Scorpius BioManufacturing website

Linkedin: Connect on Linkedin

Current Capacity: 200-L for Microbial programs and 500-L for Mammalian programs. Scorpius has capacity in both 2024 and 2025 for new programs.